Patricia A Ganz, Hanna Bandos, Tanja Španić, Sue Friedman, Volkmar Müller, Sherko Kuemmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Hideko Yamauchi, Eduardo-M de Dueñas, Anne Armstrong, Seock-Ah Im, Chuan-Gui Song, Hong Zheng, Tomasz Sarosiek, Priyanka Sharma, Cuizhi Geng, Peifen Fu, Kerstin Rhiem, Heike Frauchiger-Heuer, Pauline Wimberger, Daphné t'Kint de Roodenbeke, Ning Liao, Annabel Goodwin, Camille Chakiba-Brugère, Michael Friedlander, Keun Seok Lee, Sylvie Giacchetti, Toshimi Takano, Fernando Henao-Carrasco, Shamsuddin Virani, Frances Valdes-Albini, Susan M Domchek, Charles Bane, Edward C McCarron, Monica Mita, Giovanna Rossi, Priya Rastogi, Anitra Fielding, Richard D Gelber, Elsemieke D Scheepers, David Cameron, Judy Garber, Charles E Geyer, Andrew N J Tutt
PURPOSE: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2 , high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment. METHODS: Data were collected before random assignment, and at 6, 12, 18, and 24 months...
February 1, 2024: Journal of Clinical Oncology